Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.67 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103510 | 0.89 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1MAPTKDM4EALDH1A1 | |
| SCHEMBL3082929 | 0.89 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL3093231 | 0.89 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1ROCK2ROCK1MAPT | |
| SCHEMBL3096102 | 0.87 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL13151404 | 0.87 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL3097536 | 0.86 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL3096215 | 0.86 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1PRKD3PRKD2 | |
| SCHEMBL3103679 | 0.84 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL13151384 | 0.84 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R | |
| SCHEMBL5752613 | 0.84 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1ROCK2PRKD3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | claimed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1567151-B1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| EP-1567151-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050087-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-06-17 | — | — | WO | claimed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1567151-B1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1567151-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050087-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885ROCK2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.